Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.
Scope
- Patient potential analysis across the seven major markets - Review of the key needs supported by key opinion leaders from the US and Europe - Current and future market dynamics in the seven major markets, including analysis and forecast for current leading brands - R&D pipeline analysis with detailed profiles and forecasts of key agents, including Pfizer's Aprela
Highlights
Recovery of the HRT market following the WHI has been slow. In recent years an increase in sales in the USwhich remains the largest marketwas despite the continuous volume decrease.
Premarin remains the market leading drug accounting for over 37% of total sales in 2009 across the seven major markets. The difficulty in replicating the exact conjugated estrogen composition will continue to protect it from generic incursion for the foreseeable future.
The future of Aprela continues to be uncertain and the US Food and Drug Administration may decide not to approve the drug due to safety concerns. Nevertheless, should the drug launch Pfizer could drive market growth in an attempt to restore the multibillion market.
Reasons to Purchase
- Understand patient population and prescription dynamics - Gain insight into the unmet needs of HRT for menopausal symptoms treatment and to what extent pipeline drugs will address these issues - Identify licensing opportunities based on company portfolio and market needs
